Document Type
Review Article
Department
Cardiology; Office of the Provost
Abstract
Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.
Publication (Name of Journal)
Vascular Health and Risk Management
DOI
10.2147/VHRM.S210149
Recommended Citation
Jia, X.,
Koh, S.,
Al Rifai, M.,
Blumenthal, R. S.,
Virani, S. S.
(2020). Spotlight on Icosapent ethyl for cardiovascular risk reduction: Evidence to date. Vascular Health and Risk Management, 16, 1-10.
Available at:
https://ecommons.aku.edu/provost_office/614
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Comments
Issue no. is not provided by the author/publisher. This work was published before the author joined Aga Khan University.